StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Gain Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$19.19M. For fiscal 2025 it was -$18.62M. The highest annual figure on record is -$3.47M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.62M–
FY2024Dec 31, 2024-$20.27M–
FY2023Dec 31, 2023-$22.17M–
FY2022Dec 31, 2022-$17.71M–
FY2021Dec 31, 2021-$13.81M–
FY2020Dec 31, 2020-$3.47M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.65M–
Q1 FY2026Mar 31, 2026-$5.33M–
Q4 FY2025Dec 31, 2025-$4.44M–
Q3 FY2025Sep 30, 2025-$4.76M–
Q2 FY2025Jun 30, 2025-$5.07M–
Q1 FY2025Mar 31, 2025-$4.35M–
Q4 FY2024Dec 31, 2024-$3.31M–
Q3 FY2024Sep 30, 2024-$4.44M–
Q2 FY2024Jun 30, 2024-$8.16M–
Q1 FY2024Mar 31, 2024-$4.36M–
Q4 FY2023Dec 31, 2023-$4.38M–
Q3 FY2023Sep 30, 2023-$4.86M–
Q2 FY2023Jun 30, 2023-$7.71M–
Q1 FY2023Mar 31, 2023-$5.21M–
Q4 FY2022Dec 31, 2022-$4.54M–
Q3 FY2022Sep 30, 2022-$4.73M–
Q2 FY2022Jun 30, 2022-$5.16M–
Q1 FY2022Mar 31, 2022-$3.28M–
Q4 FY2021Dec 31, 2021-$3.20M–
Q3 FY2021Sep 30, 2021-$4.63M–
Q2 FY2021Jun 30, 2021-$3.51M–
Q1 FY2021Mar 31, 2021-$2.46M–
Q4 FY2020Dec 31, 2020-$1.61M–
Q3 FY2020Sep 30, 2020-$816.71K–
Q2 FY2020Jun 30, 2020-$530.19K–
Q1 FY2020Mar 31, 2020-$510.16K–

More Gain Therapeutics figures

See a number that looks wrong?